Viridian Therapeutics, Inc. VRDN Business Segments — Total share-based compensation expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Viridian Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpense.
The official record: Viridian Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viridian Therapeutics, Inc.'s business segments — total share-based compensation expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viridian Therapeutics, Inc.'s business segments — total share-based compensation expense?
- Viridian Therapeutics, Inc. (VRDN) reported business segments — total share-based compensation expense of $13.39M in Q1 2026.
- How has Viridian Therapeutics, Inc.'s business segments — total share-based compensation expense changed year-over-year?
- Viridian Therapeutics, Inc.'s business segments — total share-based compensation expense increased by 31.0% year-over-year, from $10.22M to $13.39M.
- What is the long-term trend for Viridian Therapeutics, Inc.'s business segments — total share-based compensation expense?
- Over 3 years (2022 to 2025), Viridian Therapeutics, Inc.'s business segments — total share-based compensation expense has grown at a 30.9% compound annual growth rate (CAGR), from $19.77M to $44.3M.
- What does business segments — total share-based compensation expense mean?
- This metric represents the total non-cash expense recognized for equity-based awards granted to employees and directors within the business segment. It serves as a measure of the cost of talent retention and incentive alignment through stock-based compensation. Investors track this to understand the impact of equity dilution and non-cash compensation on the segment's overall financial performance.